1 August 2024 false No description of principal activity Taxfiler 2024.6 15031225business:PrivateLimitedCompanyLtd2024-08-012025-07-31 150312252024-07-31 150312252024-08-012025-07-31 15031225business:AuditExempt-NoAccountantsReport2024-08-012025-07-31 15031225business:FilletedAccounts2024-08-012025-07-31 150312252025-07-31 15031225business:Director12024-08-012025-07-31 15031225business:RegisteredOffice2024-08-012025-07-31 150312252024-07-31 15031225core:AfterOneYear2025-07-31 15031225core:AfterOneYear2024-07-31 15031225core:ShareCapitalcore:PreviouslyStatedAmount2025-07-31 15031225core:ShareCapitalcore:PreviouslyStatedAmount2024-07-31 15031225core:RetainedEarningsAccumulatedLossescore:PreviouslyStatedAmount2025-07-31 15031225core:RetainedEarningsAccumulatedLossescore:PreviouslyStatedAmount2024-07-31 15031225core:PreviouslyStatedAmount2025-07-31 15031225core:PreviouslyStatedAmount2024-07-31 15031225business:SmallEntities2024-08-012025-07-31 15031225countries:EnglandWales2024-08-012025-07-31 150312252023-07-262024-07-31 iso4217:GBP xbrli:pure
Company Registration No. 15031225 (England and Wales)
Srx Pharma Ltd Unaudited accounts for the year ended 31 July 2025
Srx Pharma Ltd Unaudited accounts Contents
Page
- 2 -
Srx Pharma Ltd Company Information for the year ended 31 July 2025
Director
Shabaz Nasir Mahmood
Company Number
15031225 (England and Wales)
Registered Office
400 Gladstone Street Peterborough Cambridgeshire PE1 2BY England
Accountants
Adamson Accountants 138 Every Street Nelson Lancashire BB9 7EX
- 3 -
Srx Pharma Ltd Statement of financial position as at 31 July 2025
2025 
2024 
Notes
£ 
£ 
Current assets
Cash at bank and in hand
21,386 
9,245 
Net current assets
21,386 
9,245 
Total assets less current liabilities
21,386 
9,245 
Creditors: amounts falling due after more than one year
(7,721)
(4,372)
Net assets
13,665 
4,873 
Capital and reserves
Called up share capital
4 
4 
Profit and loss account
13,661 
4,869 
Shareholders' funds
13,665 
4,873 
For the year ending 31 July 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies. The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The director acknowledges his responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.
These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with the provisions of FRS 102 Section 1A - Small Entities. The profit and loss account has not been delivered to the Registrar of Companies.
The financial statements were approved by the Board and authorised for issue on 14 April 2026 and were signed on its behalf by
Shabaz Nasir Mahmood Director Company Registration No. 15031225
- 4 -
Srx Pharma Ltd Notes to the Accounts for the year ended 31 July 2025
1
Statutory information
Srx Pharma Ltd is a private company, limited by shares, registered in England and Wales, registration number 15031225. The registered office is 400 Gladstone Street, Peterborough, Cambridgeshire, PE1 2BY, England.
2
Compliance with accounting standards
The accounts have been prepared in accordance with the provisions of FRS 102 Section 1A Small Entities. There were no material departures from that standard.
3
Accounting policies
The principal accounting policies adopted in the preparation of the financial statements are set out below and have remained unchanged from the previous year, and also have been consistently applied within the same accounts.
Basis of preparation
The accounts have been prepared under the historical cost convention as modified by the revaluation of certain fixed assets.
Presentation currency
The accounts are presented in £ sterling.
4
Creditors: amounts falling due after more than one year
2025 
2024 
£ 
£ 
Taxes and social security
7,721 
4,372 
5
Average number of employees
During the year the average number of employees was 2 (2024: 2).
- 5 -